{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:31:50Z","timestamp":1774521110139,"version":"3.50.1"},"reference-count":53,"publisher":"Bentham Science Publishers Ltd.","issue":"3","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Diabetes mellitus is a major risk factor for chronic kidney disease (CKD) and accelerates\nkidney function decline, leading to end-stage renal disease. In addition, patients with CKD\nare at elevated risk of developing cardiovascular disease with its manifestations as coronary artery\ndisease, heart failure, arrhythmias, and sudden cardiac death through the cardiorenal connection.\nAn online regional and international expert panel of cardiologists, nephrologists, and diabetologists\nconvened in November 2021 to obtain a broad perspective on the intersection of diabetes mellitus,\nCKD, and cardiovascular disease and identified treatment gaps that can help address the unmet\nneeds of the patients in the Middle East region. The current review article summarizes the epidemiology,\npathophysiology, diagnosis, and treatment options of CKD in diabetes and discusses\nthe currently available treatment options to reduce morbidity and mortality in this high-risk population.\nThe panel discussed the roles of clinical specialties and how to simplify the patient journey.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115733998345830250417094825","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T06:07:37Z","timestamp":1748844457000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Traditional Silos: An Integrated Framework Leveraging Novel Pathways for Reducing Cardio-renal Risk in Type 2 Diabetes"],"prefix":"10.2174","volume":"22","author":[{"given":"Hani M.","family":"Sabbour","sequence":"first","affiliation":[{"name":"Department of Cardiology, Mediclinic Hospital, Abu Dhabi, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad","family":"Hassanein","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes,Dubai Hospital, Dubai, UAE"},{"name":"Postgraduate Diabetes Education, Cardiff University, Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Farghaly","sequence":"additional","affiliation":[{"name":"Dubai MedicalCollege, Head of Insurance Medical Regulation, Senior Specialist at Dubai Health Authority, Dubai, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harith M. M. S","family":"Aljubori","sequence":"additional","affiliation":[{"name":"Consultant for Nephrology and Transplantation, Al-Zahra Hospital, Sharjah, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nizar M.","family":"Attallah","sequence":"additional","affiliation":[{"name":"Consultant Nephrologist atLouisville, Nephrology Associates of Kentuckiana, Louisville, Kentucky, 40205, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Al Rukhaimi","sequence":"additional","affiliation":[{"name":"Department of Medicine, DubaiMedical College, Dubai, UAE"},{"name":"Department of Nephrology, Dubai Hospital, Dubai, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5853-4114","authenticated-orcid":true,"given":"Mostafa","family":"Al-Ashkar","sequence":"additional","affiliation":[{"name":"Private Researcher, UAE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2021","unstructured":"IDF Diabetes Atlas 2021  Available from:  https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/2021"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2105\/AJPH.2011.300290","volume":"102","author":"Hajat C.","year":"2012","unstructured":"Hajat C.; Harrison O.; Al Siksek Z.; Weqaya: A population-wide cardiovascular screening program in Abu Dhabi, United Arab Emirates. Am J Public Health  2012,102(5),909-914","journal-title":"Am J Public Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000512428","volume":"26","author":"Al Awadi F.","year":"2020","unstructured":"Al Awadi F.; Hassanein M.; Hussain H.Y.; Mohammed H.; Ibrahim G.; Khater A.; Suliman E.; Prevalence of diabetes and associated health risk factors among adults in Dubai, United Arab Emirates: Results from Dubai household survey 2019. Dubai Diabetes Endocrinol J  2020,26(4),164-173","journal-title":"Dubai Diabetes Endocrinol J"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000508833","volume":"26","author":"Alawadi F.","year":"2020","unstructured":"Alawadi F.; Hassanein M.; Suliman E.; Hussain H.Y.; Mamdouh H.; Ibrahim G.; Al Faisal W.; Monsef N.; Farghaly M.; The prevalence of diabetes and pre-diabetes among the Dubai population: Findings from Dubai household health surveys, 2014 and 2017. Dubai Diabetes Endocrinol J  2020,26(2),78-84","journal-title":"Dubai Diabetes Endocrinol J"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.tem.2020.01.007","volume":"31","author":"Mauricio D.","year":"2020","unstructured":"Mauricio D.; Alonso N.; Gratac\u00f2s M.; Chronic diabetes complications: The need to move beyond classical concepts. Trends Endocrinol Metab  2020,31(4),287-295","journal-title":"Trends Endocrinol Metab"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","year":"2022","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int  2022,102(5S),S1-S127","journal-title":"Kidney Int"},{"key":"ref=7","year":"2023","unstructured":"Incidence, prevalence, patient characteristics, and treatment modalities.  Available from:  https:\/\/usrds-adr.niddk.nih.gov\/2023\/end-stage-renal-disease\/1-incidence-prevalence-patient-characteristics-and-treatment-modalities2023"},{"key":"ref=8","year":"2019","unstructured":"Available from:  https:\/\/icldc.ae\/media\/bxqkkeeu\/outcomes-report-2019.pdf2019"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/j.ekir.2022.02.012","volume":"7","author":"Al-Ghamdi S.M.G.","year":"2022","unstructured":"Al-Ghamdi S.M.G.; Bieber B.; AlRukhaimi M.; AlSahow A.; Al Salmi I.; Al Ali F.; Al Aradi A.; Pecoits-Filho R.; Robinson B.M.; Pisoni R.L.; Al-Aradi A.; Alyousef A.; Al Salmi I.; Al-Ali F.; AlRukhaimi M.; AlGhonaim M.; Shaheen F.; Diabetes prevalence, treatment, control, and outcomes among hemodialysis patients in the gulf cooperation council countries. Kidney Int Rep  2022,7(5),1093-1102","journal-title":"Kidney Int Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/4572743","volume":"2021","author":"Naser A.Y.","year":"2021","unstructured":"Naser A.Y.; Alwafi H.; Alotaibi B.; Salawati E.; Samannodi M.; Alsairafi Z.; Alanazi A.F.R.; Dairi M.S.; Prevalence of chronic kidney diseases in patients with diabetes mellitus in the middle east: A systematic review and meta-analysis. Int J Endocrinol  2021,2021,1-9","journal-title":"Int J Endocrinol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","volume":"49","year":"2007","unstructured":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis  2007,49(2),S12-S154","journal-title":"Am J Kidney Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"S175","DOI":"10.2337\/dc22-S011","volume":"45","year":"2022","unstructured":"Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes\u20142022. Diabetes Care  2022,45(Suppl. 1),S175-S184","journal-title":"Diabetes Care"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"Jankowski J.","year":"2021","unstructured":"Jankowski J.; Floege J.; Fliser D.; B\u00f6hm M.; Marx N.; Cardiovascular disease in chronic kidney disease. Circulation  2021,143(11),1157-1172","journal-title":"Circulation"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"Marx N.","year":"2023","unstructured":"Marx N.; Federici M.; Sch\u00fctt K.; M\u00fcller-Wieland D.; Ajjan R.A.; Antunes M.J.; Christodorescu R.M.; Crawford C.; Di Angelantonio E.; Eliasson B.; Espinola-Klein C.; Fauchier L.; Halle M.; Herrington W.G.; Kautzky-Willer A.; Lambrinou E.; Lesiak M.; Lettino M.; McGuire D.K.; Mullens W.; Rocca B.; Sattar N.; Prescott E.; Cosentino F.; Abdelhamid M.; Aboyans V.; Antoniou S.; Asteggiano R.; Baumgartner I.; Buccheri S.; Bueno H.; \u010celutkien\u0117 J.; Chieffo A.; Christersson C.; Coats A.; Cosyns B.; Czerny M.; Deaton C.; Falk V.; Ference B.A.; Filippatos G.; Fisher M.; Huikuri H.; Ibanez B.; Jaarsma T.; James S.; Khunti K.; K\u00f8ber L.; Koskinas K.C.; Lewis B.S.; L\u00f8chen M-L.; McEvoy J.W.; Mihaylova B.; Mindham R.; Neubeck L.; Nielsen J.C.; Parati G.; Pasquet A.A.; Patrono C.; Petersen S.E.; Piepoli M.F.; Rakisheva A.; Rossello X.; Rossing P.; Ryd\u00e9n L.; Standl E.; Tokgozoglu L.; Touyz R.M.; Visseren F.; Volpe M.; Vrints C.; Witkowski A.; Hazarapetyan L.; Zirlik A.; Rustamova Y.; van de Borne P.; Sokolovi\u0107 \u0160.; Gotcheva N.; Milicic D.; Agathangelou P.; Vrabl\u00edk M.; Schou M.; Hasan-Ali H.; Viigimaa M.; Lautam\u00e4ki R.; Aboyans V.; Klimiashvili Z.; Kelm M.; Siasos G.; Kiss R.G.; Libungan B.; Durkan M.; Zafrir B.; Colivicchi F.; Tundybayeva M.; Byty\u00e7i I.; Mirrakhimov E.; Trusinskis K.; Saad\u00e9 G.; Badarien\u0117 J.; Banu C-A.; Magri C.J.; Boskovic A.; Hattaoui M.E.; Martens F.; Bosevski M.; Knudsen E.C.; Burchardt P.; Fontes-Carvalho R.; Vinereanu D.; Mancini T.; Beleslin B.; Martinka E.; Fras Z.; Conde A.C.; Mellbin L.; Carballo D.; Bsata W.; Mghaieth F.; Gungor B.; Mitchenko O.; Wheatcroft S.; Trigulova R.; Prescott E.; James S.; Arbelo E.; Baigent C.; Borger M.A.; Buccheri S.; Ibanez B.; K\u00f8ber L.; Koskinas K.C.; McEvoy J.W.; Mihaylova B.; Mindham R.; Neubeck L.; Nielsen J.C.; Pasquet A.A.; Rakisheva A.; Rocca B.; Rossell\u00f3 X.; Vaartjes I.; Vrints C.; Witkowski A.; Zeppenfeld K.; 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J  2023,44(39),4043-4140","journal-title":"Eur Heart J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"Alicic R.Z.","year":"2017","unstructured":"Alicic R.Z.; Rooney M.T.; Tuttle K.R.; Diabetic kidney disease. Clin J Am Soc Nephrol  2017,12(12),2032-2045","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/697010","volume":"2015","author":"Toth-Manikowski S.","year":"2015","unstructured":"Toth-Manikowski S.; Atta M.G.; Diabetic kidney disease: Pathophysiology and therapeutic targets. J Diabetes Res  2015,2015,1-16","journal-title":"J Diabetes Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"Agarwal R.","year":"2021","unstructured":"Agarwal R.; Kolkhof P.; Bakris G.; Bauersachs J.; Haller H.; Wada T.; Zannad F.; Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J  2021,42(2),152-161","journal-title":"Eur Heart J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/nep.13860","volume":"26","author":"Sugahara M.","year":"2021","unstructured":"Sugahara M.; Pak W.L.W.; Tanaka T.; Tang S.C.W.; Nangaku M.; Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton)  2021,26(6),491-500","journal-title":"Nephrology (Carlton)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41598-018-37690-5","volume":"9","author":"S\u00e1rk\u00f6zy M.","year":"2019","unstructured":"S\u00e1rk\u00f6zy M.; G\u00e1sp\u00e1r R.; Zvara \u00c1.; Siska A.; K\u0151v\u00e1ri B.; Sz\u0171cs G.; M\u00e1rv\u00e1nyk\u00f6vi F.; Kov\u00e1cs M.G.; Di\u00f3szegi P.; Bodai L.; Zsindely N.; Pipicz M.; G\u00f6m\u00f6ri K.; Kiss K.; Bencsik P.; Cserni G.; Pusk\u00e1s L.G.; F\u00f6ldesi I.; Thum T.; B\u00e1tkai S.; Csont T.; Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212. Sci Rep  2019,9(1),1302","journal-title":"Sci Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1161\/CIRCRESAHA.122.321748.","volume":"132","author":"Schuett K.","year":"2023","unstructured":"Schuett K.; Marx N.; Lehrke M.; The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy. Circ Res  2023,132(8),902-914","journal-title":"Circ Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jchf.2021.09.001","volume":"9","author":"Rossignol P.","year":"2021","unstructured":"Rossignol P.; A step forward toward a new treatment paradigm in the cardiorenal continuum. JACC Heart Fail  2021,9(11),821-823","journal-title":"JACC Heart Fail"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1681\/ASN.2012070718","volume":"24","author":"Afkarian M.","year":"2013","unstructured":"Afkarian M.; Sachs M.C.; Kestenbaum B.; Hirsch I.B.; Tuttle K.R.; Himmelfarb J.; de Boer I.H.; Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol  2013,24(2),302-308","journal-title":"J Am Soc Nephrol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-019-0837-x","volume":"18","author":"Bramlage P.","year":"2019","unstructured":"Bramlage P.; Lanzinger S.; van Mark G.; Hess E.; Fahrner S.; Heyer C.H.J.; Friebe M.; Seufert J.; Danne T.; Holl R.W.; Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: An analysis of the German DPV and DIVE databases. Cardiovasc Diabetol  2019,18(1),33","journal-title":"Cardiovasc Diabetol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","volume":"380","author":"Fox C.S.","year":"2012","unstructured":"Fox C.S.; Matsushita K.; Woodward M.; Bilo H.J.G.; Chalmers J.; Heerspink H.J.L.; Lee B.J.; Perkins R.M.; Rossing P.; Sairenchi T.; Tonelli M.; Vassalotti J.A.; Yamagishi K.; Coresh J.; de Jong P.E.; Wen C.P.; Nelson R.G.; Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet  2012,380(9854),1662-1673","journal-title":"Lancet"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"B35","DOI":"10.2337\/diacare.23.7.882","volume":"23","author":"Gerstein H.C.","year":"2000","unstructured":"Gerstein H.C.; Mann J.F.; Pogue J.; Dinneen S.F.; Hall\u00e9 J.P.; Hoogwerf B.; Joyce C.; Rashkow A.; Young J.; Zinman B.; Yusuf S.; Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. Diabetes Care  2000,23(Suppl. 2),B35-B39","journal-title":"Diabetes Care"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/kisup.2012.75","volume":"3","year":"2013","unstructured":"Work Group Membership. Kidney Int Suppl  2013,3(1),3","journal-title":"Kidney Int Suppl"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.2337\/dc15-S012","volume":"38","author":"Complications M.","year":"2015","unstructured":"Complications M.; Care F.; Microvascular complications and foot care. Diabetes Care  2015,38(Suppl. 1),S58-S66","journal-title":"Diabetes Care"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","volume":"345","author":"Brenner B.M.","year":"2001","unstructured":"Brenner B.M.; Cooper M.E.; de Zeeuw D.; Keane W.F.; Mitch W.E.; Parving H.H.; Remuzzi G.; Snapinn S.M.; Zhang Z.; Shahinfar S.; Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med  2001,345(12),861-869","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"Lewis E.J.","year":"2001","unstructured":"Lewis E.J.; Hunsicker L.G.; Clarke W.R.; Berl T.; Pohl M.A.; Lewis J.B.; Ritz E.; Atkins R.C.; Rohde R.; Raz I.; Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med  2001,345(12),851-860","journal-title":"N Engl J Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/dom.14601","volume":"24","author":"Chaudhuri A.","year":"2022","unstructured":"Chaudhuri A.; Ghanim H.; Arora P.; Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials. Diabetes Obes Metab  2022,24(3),365-376","journal-title":"Diabetes Obes Metab"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Baigent C.","year":"2022","unstructured":"Baigent C.; Emberson J.R.; Haynes R.; Herrington W.G.; Judge P.; Landray M.J.; Mayne K.J.; Ng S.Y.A.; Preiss D.; Roddick A.J.; Staplin N.; Zhu D.; Anker S.D.; Bhatt D.L.; Brueckmann M.; Butler J.; Cherney D.Z.I.; Green J.B.; Hauske S.J.; Haynes R.; Heerspink H.J.L.; Herrington W.G.; Inzucchi S.E.; Jardine M.J.; Liu C-C.; Mahaffey K.W.; McCausland F.R.; McGuire D.K.; McMurray J.J.V.; Neal B.; Neuen B.L.; Packer M.; Perkovic V.; Sabatine M.S.; Solomon S.D.; Vaduganathan M.; Wanner C.; Wheeler D.C.; Wiviott S.D.; Zannad F.; Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet  2022,400(10365),1788-1801","journal-title":"Lancet"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcell.2019.00314","volume":"7","author":"Provenzano M.","year":"2019","unstructured":"Provenzano M.; Coppolino G.; De Nicola L.; Serra R.; Garofalo C.; Andreucci M.; Bolignano D.; Unraveling cardiovascular risk in renal patients: A new take on old tale. Front Cell Dev Biol  2019,7,314","journal-title":"Front Cell Dev Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/ki.2010.536","volume":"79","author":"Van der Velde M.","year":"2011","unstructured":"Van der Velde M.; Matsushita K.; Coresh J.; Astor B.C.; Woodward M.; Levey A.S.; de Jong P.E.; Gansevoort R.T.; van der Velde M.; Matsushita K.; Coresh J.; Astor B.C.; Woodward M.; Levey A.S.; de Jong P.E.; Gansevoort R.T.; Levey A.; El-Nahas M.; Eckardt K.U.; Kasiske B.L.; Ninomiya T.; Chalmers J.; Macmahon S.; Tonelli M.; Hemmelgarn B.; Sacks F.; Curhan G.; Collins A.J.; Li S.; Chen S.C.; Hawaii Cohort K.P.; Lee B.J.; Ishani A.; Neaton J.; Svendsen K.; Mann J.F.; Yusuf S.; Teo K.K.; Gao P.; Nelson R.G.; Knowler W.C.; Bilo H.J.; Joosten H.; Kleefstra N.; Groenier K.H.; Auguste P.; Veldhuis K.; Wang Y.; Camarata L.; Thomas B.; Manley T.; Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int  2011,79(12),1341-1352","journal-title":"Kidney Int"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"Matsushita K.","year":"2010","unstructured":"Matsushita K.; van der Velde M.; Astor B.C.; Woodward M.; Levey A.S.; de Jong P.E.; Coresh J.; Gansevoort R.T.; Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet  2010,375(9731),2073-2081","journal-title":"Lancet"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"99","author":"Cheung A.K.","year":"2021","unstructured":"Cheung A.K.; Chang T.I.; Cushman W.C.; Furth S.L.; Hou F.F.; Ix J.H.; Knoll G.A.; Muntner P.; Pecoits-Filho R.; Sarnak M.J.; Tobe S.W.; Tomson C.R.V.; Mann J.F.E.; KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int  2021,99(3),S1-S87","journal-title":"Kidney Int"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc06-1998","volume":"30","author":"Makino H.","year":"2007","unstructured":"Makino H.; Haneda M.; Babazono T.; Moriya T.; Ito S.; Iwamoto Y.; Kawamori R.; Takeuchi M.; Katayama S.; Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care  2007,30(6),1577-1578","journal-title":"Diabetes Care"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2337\/dc23-S011","volume":"46","author":"Nuha A.","year":"2023","unstructured":"Nuha A.; Aleppo G.; Aroda V.R.; Chronic kidney disease and risk management: Standards of care in diabetes\u20142023. Diabetes Care  2023,46(1),S191-S202","journal-title":"Diabetes Care"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","volume":"3","author":"De Zeeuw D.","year":"2015","unstructured":"De Zeeuw D.; Anzalone D.A.; Cain V.A.; Cressman M.D.; Heerspink H.J.L.; Molitoris B.A.; Monyak J.T.; Parving H.H.; Remuzzi G.; Sowers J.R.; Vidt D.G.; Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial. Lancet Diabetes Endocrinol  2015,3(3),181-190","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"744","DOI":"10.34067\/KID.0007072021","volume":"3","author":"Ghuman Jasleen K.","year":"2022","unstructured":"Ghuman Jasleen K.; Tuttle Katherine R.; Perspective on nonsteroidal mineralocorticoid receptor antagonism in diabetic kidney disease. Kidney  2022,3(4),744-748","journal-title":"Kidney"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"645187","DOI":"10.3389\/fmed.2021.645187","volume":"8","author":"Shabaka A.","year":"2021","unstructured":"Shabaka A.; Cases-Corona C.; Fernandez-Juarez G.; Therapeutic insights in chronic kidney disease progression. Front Med (Lausanne)  2021,8(645187),645187","journal-title":"Front Med (Lausanne)"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1111\/bph.15747","volume":"179","author":"Kintscher U.","year":"2022","unstructured":"Kintscher U.; Bakris G.L.; Kolkhof P.; Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol  2022,179(13),3220-3234","journal-title":"Br J Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"Bakris G.L.","year":"2019","unstructured":"Bakris G.L.; Agarwal R.; Anker S.D.; Pitt B.; Ruilope L.M.; Nowack C.; Kolkhof P.; Ferreira A.C.; Schloemer P.; Filippatos G.; Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol  2019,50(5),333-344","journal-title":"Am J Nephrol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"Ruilope L.M.","year":"2019","unstructured":"Ruilope L.M.; Agarwal R.; Anker S.D.; Bakris G.L.; Filippatos G.; Nowack C.; Kolkhof P.; Joseph A.; Mentenich N.; Pitt B.; Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol  2019,50(5),345-356","journal-title":"Am J Nephrol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2022.08.040","volume":"103","author":"Bakris G.L.","year":"2023","unstructured":"Bakris G.L.; Ruilope L.M.; Anker S.D.; Filippatos G.; Pitt B.; Rossing P.; Fried L.; Roy-Chaudhury P.; Sarafidis P.; Ahlers C.; Brinker M.; Joseph A.; Lawatscheck R.; Agarwal R.; A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int  2023,103(1),196-206","journal-title":"Kidney Int"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"Agarwal R.","year":"2022","unstructured":"Agarwal R.; Filippatos G.; Pitt B.; Anker S.D.; Rossing P.; Joseph A.; Kolkhof P.; Nowack C.; Gebel M.; Ruilope L.M.; Bakris G.L.; Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J  2022,43(6),474-484","journal-title":"Eur Heart J"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2021070942","volume":"33","author":"Agarwal R.","year":"2022","unstructured":"Agarwal R.; Joseph A.; Anker S.D.; Filippatos G.; Rossing P.; Ruilope L.M.; Pitt B.; Kolkhof P.; Scott C.; Lawatscheck R.; Wilson D.J.; Bakris G.L.; Hyperkalemia risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol  2022,33(1),225-237","journal-title":"J Am Soc Nephrol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"107701","DOI":"10.1016\/j.pharmthera.2020.107701","volume":"219","author":"Cosimato C.","year":"2021","unstructured":"Cosimato C.; Agoritsas T.; Mavrakanas T.A.; Mineralocorticoid receptor antagonists in patients with chronic kidney disease. Pharmacol Ther  2021,219,107701","journal-title":"Pharmacol Ther"},{"key":"ref=48","year":"2022","unstructured":"Trial of pirfenidone to prevent progression in chronic kidney disease (TOP-CKD). Veterans Medical Research Foundation 2022"},{"key":"ref=49","year":"2022","unstructured":"Pentoxifylline in Diabetic Kidney Disease (PTXRx).  2022"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"21501327211003683","DOI":"10.1177\/21501327211003683","volume":"12","author":"Christofides E.A.","year":"2021","unstructured":"Christofides E.A.; Desai N.; Optimal early diagnosis and monitoring of diabetic kidney disease in type 2 diabetes mellitus: Addressing the barriers to albuminuria testing. J Prim Care Community Health  2021,12,21501327211003683","journal-title":"J Prim Care Community Health"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/dom.13942","volume":"22","author":"Stephens J.W.","year":"2020","unstructured":"Stephens J.W.; Brown K.E.; Min T.; Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk. Diabetes Obes Metab  2020,22(S1)(Suppl. 1),32-45","journal-title":"Diabetes Obes Metab"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2337\/dc19-0349","volume":"42","author":"Vistisen D.","year":"2019","unstructured":"Vistisen D.; Andersen G.S.; Hulman A.; Persson F.; Rossing P.; J\u00f8rgensen M.E.; Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function\u2014even without albuminuria. Diabetes Care  2019,42(10),1886-1894","journal-title":"Diabetes Care"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"728320","DOI":"10.3389\/fcdhc.2021.728320","volume":"2","author":"Sonmez A.","year":"2021","unstructured":"Sonmez A.; Challenges in the prevention and management of diabetic kidney diseases. Front Clin Diabetes Healthc  2021,2(728320),728320","journal-title":"Front Clin Diabetes Healthc"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733998345830250417094825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/242409\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115733998345830250417094825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:19:55Z","timestamp":1774516795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/242409\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115733998345830250417094825","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-09-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e15733998345830"}}